Literature DB >> 17906888

Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis.

C Lahiff1, O B Khiaron, N Nolan, G A Chadwick.   

Abstract

BACKGROUND: Pneumocystis carinii pneumonia (PCP) is a rare form of pneumonia associated with immune-suppression. It is common in patients with AIDS and with a CD4 count of less than 200 cells/mm(3). We report a case of PCP secondary to immune-suppression in a 41-year-old man with psoriatic arthritis being treated with the immune-modulatory agent etanercept.
METHODS: Diagnosis of PCP was made histologically using tissue obtained via transbronchial biopsy.
RESULTS: There was a good response to standard treatment with high-dose co-trimoxazole.
CONCLUSION: This report highlights a recognised but previously unreported complication of etanercept.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17906888     DOI: 10.1007/s11845-007-0087-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  12 in total

Review 1.  New drugs for rheumatoid arthritis.

Authors:  Nancy J Olsen; C Michael Stein
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 2.  Infectious complications of tumor necrosis factor-alpha antagonists.

Authors:  Mohanad Bakleh; Imad Tleyjeh; Eric L Matteson; Douglas R Osmon; Elie F Berbari
Journal:  Int J Dermatol       Date:  2005-06       Impact factor: 2.736

3.  Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody.

Authors:  Shunsuke Mori; Fumiya Imamura; Chikage Kiyofuji; Kanako Ito; Yukinori Koga; Izumi Honda; Mineharu Sugimoto
Journal:  Mod Rheumatol       Date:  2006       Impact factor: 3.023

4.  Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection.

Authors:  K A Oien; A Black; J A Hunter; R Madhok
Journal:  Br J Rheumatol       Date:  1995-07

5.  Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome.

Authors: 
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

6.  Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.

Authors:  T R Navin; C B Beard; L Huang; C del Rio; S Lee; N J Pieniazek; J L Carter; T Le; A Hightower; D Rimland
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

Review 7.  Low-dose methotrexate as a risk factor for Pneumocystis carinii pneumonia.

Authors:  S Krebs; R B Gibbons
Journal:  Mil Med       Date:  1996-01       Impact factor: 1.437

8.  Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue diseases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases.

Authors:  K Saito; S Nakayamada; K Nakano; M Tokunaga; S Tsujimura; K Nakatsuka; T Adachi; Y Tanaka
Journal:  Rheumatology (Oxford)       Date:  2004-02-03       Impact factor: 7.580

Review 9.  The laboratory evaluation of opportunistic pulmonary infections.

Authors:  J H Shelhamer; V J Gill; T C Quinn; S W Crawford; J A Kovacs; H Masur; F P Ognibene
Journal:  Ann Intern Med       Date:  1996-03-15       Impact factor: 25.391

10.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

View more
  5 in total

Review 1.  Safety of biologic therapy in rheumatoid arthritis.

Authors:  Robert S Woodrick; Eric M Ruderman
Journal:  Nat Rev Rheumatol       Date:  2011-10-11       Impact factor: 20.543

Review 2.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

3.  Glycosphingolipids mediate pneumocystis cell wall β-glucan activation of the IL-23/IL-17 axis in human dendritic cells.

Authors:  Eva M Carmona; Theodore J Kottom; Deanne M Hebrink; Teng Moua; Raman-Deep Singh; Richard E Pagano; Andrew H Limper
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-16       Impact factor: 6.914

4.  Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.

Authors:  Matthew R Gingo; Lorrie Lucht; Kieran R Daly; Kpandja Djawe; Frank J Palella; Alison G Abraham; Jay H Bream; Mallory D Witt; Lawrence A Kingsley; Karen A Norris; Peter D Walzer; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2011-07-01       Impact factor: 3.731

5.  Increasing Pneumocystis pneumonia, England, UK, 2000-2010.

Authors:  Rishma Maini; Katherine L Henderson; Elizabeth A Sheridan; Theresa Lamagni; Gordon Nichols; Valerie Delpech; Nick Phin
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.